Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT2P
- Development stage
- Preclinical
- Lead developer
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
01
Overview
FT2P is a novel bacteriophage (myovirus) isolated from hospital wastewater that exhibits bactericidal activity against vancomycin-resistant *Enterococcus faecium* (VREfm) and *Enterococcus faecalis*. Developed by researchers at the IIS-Hospital Universitario Fundación Jiménez Díaz and collaborating institutions, FT2P has demonstrated stability across a wide pH range (4.5–10.5) and at physiological temperatures, as well as strain-dependent lytic efficacy against multidrug-resistant clinical strains of *Enterococcus*. It is being preclinically evaluated as a potential precision antimicrobial therapy for complex infections, such as bloodstream and catheter-associated infections caused by VREfm.
- Other names
- bacteriophage FT2Pphage FT2P
Beyond the preview
Go deeper on FT2P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT2P.